SGLT-2 inhibitors reduce adverse CV events associated with restenosis in stents in patients with type 2 diabetes.

Published Date: 13 Mar 2023

Italy: Treatment with SGLT2 inhibitors in patients with type 2 diabetes (T2D) is associated with a reduced risk of restenosis in the stent...

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Additional Proof of the Different Cognitive Effects of ARSIs for Prostate Cancer.

2.

Year in Review: Chronic Lymphocytic Leukemia

3.

In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.

4.

CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma

5.

Response Duration After Stopping Enfortumab Vedotin in Bladder Cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot